δ1-Testolactone

CAS: 968-93-4

Ref. TR-T154800

Informação sobre produto

• Nome: δ1-Testolactone
• Sinónimos: (4aS,4bR,10aR,10bS,12aS)-3,4,4a,5,6,10a,10b,11,12,12a-Decahydro-10a,12a-dimethyl-2H-phenanthro[2,1-b]pyran-2,8(4bH)-dione, 13,17-Secoandrosta-1,4-dien-17-oic acid, 13-hydroxy-3-oxo-, δ-lactone (6CI,8CI), D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione, Testololactone, 1-dehydro- (7CI), (4aS,4bR,10aR,10bS,12aS)-3,4,4a,5,6,10a,10b,11,12,12a-Decahydro-10a,12a-dimethyl-2H-phenanthro[2,1-b]pyran-2,8(4bH)-dione, 1,2-Dehydrotestololactone, 1,2-Didehydrotestololactone, 1-Dehydrotestololactone, 17a-Oxa-D-homo-1,4-androstadiene-3,17-dione, 2H-Phenanthro[2,1-b]pyran-2,8(4bH)-dione, 3,4,4a,5,6,10a,10b,11,12,12a-decahydro-10a,12a-dimethyl-, [4aS-(4aα,4bβ,10aβ,10bα,12aβ)]-, Fludestrin, NSC 23759, SQ 9538, Teolit, Teslac, Teslak, Testolacton, Testolactone, Δ1-Dehydrotestololactone
• Marca: TRC
• Descrição: Applications Antineoplastic; non-selective steroidal aromatase inhibitor that prevents the conversion from androgen to estrogen. Used in in the treatment of familial male precocious puberty. An effective anti-tumor agent.References Dunkel, L.: Mol. Cell. Endocrinol., 254, 207 (2006); Eugster, E. A.: Treat. Endocrinol., 3, 141 (2004); Holbeck, S.L. et al.: Mol. Cancer Therap., 9, 1451 (2010)

Propriedades químicas

• Peso molecular: 300.39
• Fórmula: C₁₉H₂₄O₃
• Cor/forma: Neat
• InChI: InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1
• Chave InChI: InChIKey=BPEWUONYVDABNZ-DZBHQSCQSA-N
• SMILES: C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CCC(=O)O2